Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95237
UPID:
LRAT_HUMAN
Alternative names:
Phosphatidylcholine--retinol O-acyltransferase
Alternative UPACC:
O95237; A8K983; Q8N716
Background:
Lecithin retinol acyltransferase (LRAT), also known as Phosphatidylcholine--retinol O-acyltransferase, plays a pivotal role in vision by transferring the acyl group from phosphatidylcholine to all-trans retinol, forming all-trans retinyl esters. These esters serve as storage forms of vitamin A, essential for the survival of cone photoreceptors and proper rod photoreceptor cell morphology.
Therapeutic significance:
LRAT's critical function in vision, particularly in the synthesis of 11-cis-retinaldehyde, a key component of rhodopsin and cone photopigments, links it to Leber congenital amaurosis 14, a severe dystrophy of the retina. Understanding the role of LRAT could open doors to potential therapeutic strategies for this and related visual impairments.